Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis.

It is well accepted that cancer develops following the sequential accumulation of multiple alterations, but how the temporal order of events affects tumor initiation and/or progression remains largely unknown. Here, we describe a mouse model that allows for temporally distinct cancer mutations. By integrating a Flp-inducible allele of K-ras(G12D) with established methods for Cre-mediated p53 deletion, we were able to separately control the mutation of these commonly associated cancer genes in vitro and in vivo. We show that delaying p53 deletion relative to K-ras(G12D) activation reduced tumor burden in a mouse model of soft-tissue sarcoma, suggesting that p53 strongly inhibits very early steps of transformation in the muscle. Furthermore, using in vivo RNA interference, we implicate the p53 target gene p21 as a critical mediator in this process, highlighting cell-cycle arrest as an extremely potent tumor suppressor mechanism.

[1]  T. Jacks,et al.  Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras , 2010, Proceedings of the National Academy of Sciences.

[2]  Lawrence A. Donehower,et al.  20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.

[3]  S. Lowe,et al.  Tumor suppressive functions of p53. , 2009, Cold Spring Harbor perspectives in biology.

[4]  L. Donehower,et al.  Timed Somatic Deletion of p53 in Mice Reveals Age-Associated Differences in Tumor Progression , 2009, PloS one.

[5]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[6]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[7]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[8]  Jan Grimm,et al.  A spatially and temporally restricted mouse model of soft tissue sarcoma , 2007, Nature Medicine.

[9]  A. Efeyan,et al.  Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression , 2007, Oncogene.

[10]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[11]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[12]  C. S. Raymond,et al.  High-Efficiency FLP and ΦC31 Site-Specific Recombination in Mammalian Cells , 2007, PloS one.

[13]  G. Evan,et al.  The pathological response to DNA damage does not contribute to p53-mediated tumour suppression , 2006, Nature.

[14]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[15]  F. Zindy,et al.  Arf tumor suppressor promoter monitors latent oncogenic signals in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Michael T. McManus,et al.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference , 2003, Nature Genetics.

[17]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[18]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[19]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[20]  Philippe Soriano,et al.  An Flp indicator mouse expressing alkaline phosphatase from the ROSA26 locus , 2001, Nature Genetics.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  M. Vooijs,et al.  Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse , 1998, Oncogene.

[23]  P. Angrand,et al.  Improved properties of FLP recombinase evolved by cycling mutagenesis , 1998, Nature Biotechnology.

[24]  H. Taubert,et al.  Soft Tissue Sarcomas and p53 Mutations , 1998, Molecular medicine.

[25]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[26]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[27]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[28]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[29]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[30]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.